Region Halland
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The research at Region Halland focuses on cardiovascular diseases such as atrial fibrillation, heart failure with preserved ejection fraction, and stroke prevention in patients with kidney impairment.
- Anticoagulation strategies to reduce stroke in chronic kidney disease patients with atrial fibrillation
- Evaluation of mineralocorticoid receptor antagonists to lower heart‑failure hospitalizations
- Pragmatic registry‑based trials assessing real‑world outcomes in heart failure with preserved ejection fraction
Ongoing studies aim to improve survival and quality of life for individuals with complex heart conditions, leveraging the hospital’s multidisciplinary expertise.
Female Urogenital & Pregnancy
Trials at the Varberg clinic explore safe and effective methods for labour induction, comparing outpatient and inpatient settings to enhance maternal care.
- Outpatient labour induction safety and efficacy
- Patient‑centered protocols for managing pregnancy complications
- Impact of induction setting on maternal and neonatal outcomes
The research supports evidence‑based guidelines that aim to improve obstetric outcomes for women throughout the region.
Hematologic & Lymphatic Disorders
The site conducts studies on multiple myeloma, focusing on innovative immunotherapies and strategies for treatment discontinuation.
- Bispecific antibody therapy and remission duration in multiple myeloma
- Minimal residual disease assessment after combination regimens
- Strategies for treatment‑free intervals following intensive therapy
Findings aim to extend survival while reducing treatment burden for patients with plasma‑cell malignancies.
Hormonal & Metabolic Disorders
Research includes investigations of new agents to preserve insulin secretion in type 1 diabetes and to slow chronic kidney disease progression.
- Ixekizumab effect on residual insulin production in newly diagnosed type 1 diabetes
- Combination of baxdrostat and dapagliflozin to protect kidney function
- Hormone‑modulating therapies targeting metabolic control
These trials seek to preserve organ function and improve long‑term outcomes for individuals with endocrine disorders.
Oncology & Cancer Research
Clinical work at the hospital targets neoplasms, evaluating cutting‑edge therapies and post‑transplant care for solid and blood cancers.
- Autologous stem‑cell transplantation protocols for transplant‑eligible myeloma patients
- Assessment of disease‑free survival after innovative drug combinations
- Integration of targeted agents into standard oncologic practice
By partnering with national cancer networks, the site contributes to advancing therapeutic options for Swedish patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 13 therapeutic areas and 15 of 95 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 83 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 15 by active trials.
- 1Region Skane3active
lock +14 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Region Skane6trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Region Halland
lock Showing 1 of 36 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy | Sanofi-Aventis Recherche & Developpement | Phase II | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 95 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 3 | Unknown | 2017-12-06 | 2020-08-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.